GE HealthCare Technologies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GEHC research report →
Range $67 – $95
Price Chart
About the company
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients.
- CEO
- Peter J. Arduini
- IPO
- 2022
- Employees
- 54,000
- HQ
- Chicago, IL, US
AI snapshot
Six angles, distilled from the data.
The stock is in a multi-month uptrend and still trades well above its 200-day average, with the 50-day also above the 200-day. It sits near the upper end of its 52-week range, which points to a constructive trend regime rather than a deep-value setup.
Street sentiment is constructive: 13 Buy and 7 Hold ratings with a Buy consensus, and the average target at $81.22 sits below the current share price while the median is $80. Recent action has been mostly constructive too, with Barclays, Citi, and BofA all raising targets in late October.
The earnings profile is favorable: GEHC has beaten EPS in 7 of the last 8 quarters, including a 10.7% beat in the latest report. Next-year EPS is modeled at 5.5025 versus 4.73 TTM, so shareholders should watch whether margin discipline and demand keep the growth path intact.
No notable discretionary insider buying or selling. Recent filings were award-type grants to the CFO and a PCS executive, which are compensation-related rather than a trading signal, so the pattern reads as neutral.
Profitability is solid, with gross margin at 39.3% and operating margin at 13.75%. Growth is healthy too, with revenue up 7.2% year over year and earnings up 39%, while free cash flow of $2.47 billion and FCF yield of 6.53% support the balance sheet.
GEHC looks like a premium-quality medtech name with steady execution, but it also carries a valuation above a typical value screen at 17.07 times earnings. The setup favors a company that can defend margins and cash flow while competing in imaging, ultrasound, monitoring, and diagnostics.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.46B
- P/E
- 17.27
- Fwd P/E
- 16.06
- PEG
- -7.61
- P/S
- 1.71
- P/B
- 3.19
- EV/EBITDA
- 11.67
- Div Yield
- 0.18%
- Gross Margin
- 39.94%
- Op Margin
- 13.33%
- Net Margin
- 10.01%
- ROE
- 19.85%
- ROIC
- 7.75%
Latest fiscal year · YoY change
- Revenue
- $20.63B+4.8%
- Gross Profit
- $8.25B+0.5%
- Op Income
- $2.76B
- Net Income
- $2.08B+4.6%
- EPS
- $4.56+4.3%
- OCF Growth
- +1.9%
- FCF Growth
- -2.8%
- 52W High
- $89.77
- 52W Low
- $58.75
- 50D MA
- $71.86
- 200D MA
- $69.98
- Beta
- 0.77
- RSI (14)
- 61
- Avg Volume
- 3.68M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
GE Healthcare delivered a strong third quarter with 6.2% organic revenue growth, 180 basis points of margin expansion, and an increased full-year outlook, while highlighting strong PDX momentum and improving PCS execution.· October 28, 2026
- Revenue was $5.5 billion, up 6.2% organically; adjusted EPS was $1.34, up 25.1%; adjusted EBIT margin was 16.6%, up 180 basis points.
- Organic orders grew 4%, book-to-bill was 1.03x, and backlog ended at $23.7 billion, up $2.5 billion or 12% year over year.
- Free cash flow was $793 million, up $310 million versus the prior year; the company also raised its cash dividend by 14%.
- Management raised full-year 2026 guidance across the board: about 4% organic revenue growth, 15.5% to 15.7% adjusted EBIT margin, $4.95 to $5.05 adjusted EPS, and free cash flow above $1.6 billion.
- China improved sequentially, PDX continued to post at least high-single-digit growth for the fifth straight quarter, and PCS improved sharply after supply-chain and execution fixes.
GE Healthcare reported third-quarter revenue of $5.5 billion, up 6.2% organically. Reported product revenue grew 6.7% and service revenue grew 8.1%; organic orders rose 4%; book-to-bill was 1.03x; and backlog was $23.7 billion, up $2.5 billion or 12% year over year. Adjusted EBIT margin was 16.6%, up 180 basis points, and adjusted EPS was $1.34, up 25.1%. Free cash flow was $793 million, up $310 million from the prior year. For the full year 2026, the company now expects approximately 4% organic revenue growth, adjusted EBIT margin of 15.5% to 15.7%, adjusted EPS of $4.95 to $5.05, free cash flow in excess of $1.6 billion, an adjusted effective tax rate of 20% to 21%, and an FX tailwind to revenue of about 75 basis points.
Peter Arduini emphasized that the quarter reflected broad-based demand, stronger execution, and margin expansion across all segments. He said Heartbeat is improving commercial and operational simplification, and pointed to regulatory milestones, new product launches, and the planned SoFi Bioscience acquisition as examples of the company’s growth strategy. His tone was constructive and confident, especially on PDX, ultrasound, and Vercado, and he repeatedly said the business is positioned well into Q4, 2027, and 2028.
William Grogan highlighted the quarter’s top-line and bottom-line beat versus expectations, with $5.5 billion of revenue, 16.6% adjusted EBIT margin, $1.34 adjusted EPS, and $793 million of free cash flow. He said margin expansion came from volume, pricing and cost mitigation actions, and lower tariff expense, partly offset by inflation in memory chips and oil-related supply-chain costs. He also noted the company raised its dividend 14% and reaffirmed that the full-year outlook now assumes $4.95 to $5.05 adjusted EPS and free cash flow above $1.6 billion.
Analysts focused on capex demand, backlog lumpiness, Vercado’s path to a $500 million exit rate by 2028, China, tariffs, pricing, and the PCS turnaround. Management said it is not seeing a material pullback in scan or contrast data, described the orders pipeline as strong, and attributed lower book-to-bill to timing on large deals rather than weaker demand. On Vercado, management said it feels very good about the $500 million exiting 2028 target, while on tariffs it said the biggest uncertainty is Section 32 and that mitigation will come from pricing, supply-chain actions, and productivity. PCS was described as improving due to better supplier execution and daily management, with no impact from the leadership change on the strategic review timeline.
The call showed broad operational improvement, with stronger growth in AIS, PDX, and a sharp PCS recovery, plus expanding margins and cash flow. Management sounded confident that backlog, orders, and new product launches can support continued growth into 2027 and 2028, especially in imaging, radiopharma, and ultrasound.
Management acknowledged ongoing uncertainty around tariffs, inflation, and Section 32, and said these pressures are not fully offset yet. PCS still faces a muted comparison in Q4 because of last year’s product-hold release, and management cautioned that China is improving but still has “lots of wood to chop” before growth normalizes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 452.14M
- Float Shares
- 450.65M
of shares held by institutions
1,275 13F filers
Buy/sell ratio 0.15. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GEHC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 8, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 6, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Terri SewellHouse · AL07 | Sell | Mar 25, 26 | Filing → |
| Warren DavidsonHouse · OH08 | Sell | Mar 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Austin ScottHouse · GA08 | Sell | Mar 27, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 52.28M | ▲ 267.06K |
| Dodge & Cox | 37.86M | ▲ 6.55M |
| Blackrock, Inc. | 37.47M | ▲ 1.48M |
| Vanguard Capital Management LLC | 29.72M | ▲ 860.17K |
| State Street Corp | 21.00M | ▲ 135.55K |
| Vanguard Portfolio Management LLC | 20.28M | ▲ 1.09M |
| Invesco Ltd. | 18.45M | ▲ 157.53K |
| Harris Associates L P | 15.33M | ▼ 265.32K |
| Barrow Hanley Mewhinney & Strauss LLC | 13.77M | ▲ 314.05K |
| Geode Capital Management, LLC | 12.94M | ▲ 66.61K |
| Hotchkis & Wiley Capital Management LLC | 12.25M | ▲ 2.28M |
| Jpmorgan Chase & Co | 8.14M | ▼ 2.19M |
Held by 1,813 ETFs
Biggest fund positions in GEHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Sandy Neal Joseph | other | 1,018 |
| Nov 16, 26 | Sandy Neal Joseph | other | 2,589 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
| Nov 16, 26 | Sandy Neal Joseph | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GEHC coverage
Recent articles, reports, and earnings notes.

GE HealthCare (GEHC): Imaging and Dx Drive the Case
GE HealthCare is gaining traction from strong imaging and pharmaceutical diagnostics growth, but Patient Care Solutions remains a drag. The stock looks fairly valued with a Hold rating and a $76 fair value estimate.

GE HealthCare Technologies Inc. (GEHC) rises on deep earnings beat
GE HealthCare Technologies Inc. (GEHC) rises after a broad Q3 beat that went beyond the headline. This deep-dive covers margin expansion, segment strength, cash flow gains, and the company’s raised full-year outlook, showing how volume, pricing, and execution drove the move.

GE HealthCare Technologies Inc. (GEHC) rises on earnings beats
GE HealthCare Technologies Inc. (GEHC) rises after reporting earnings beats, lifting shares 8.0% as investors react to stronger-than-expected results and improved outlook.
Want a deeper read on GEHC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
GE HealthCare Foundation announces 2026 grants to expand maternal and pediatric care in underserved communities
businesswire.com · Nov 20
GEHC Advances Manganese-Based MRI Agent to Phase 3 After Positive Data
zacks.com · Nov 20
GE HealthCare introduces new Imaging 360 features to simplify protocol management and support radiology workflows
businesswire.com · Nov 20
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
zacks.com · Nov 19
Why GE HealthCare Technologies (GEHC) is a Top Stock for the Long-Term
zacks.com · Nov 19
GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial
businesswire.com · Nov 19
GE HealthCare Expands Global Research Network for Photon-Counting CT
zacks.com · Nov 18
GE HealthCare brings advanced visualization into InteleViewer to support radiology workflows
businesswire.com · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice